These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11717571)

  • 1. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.
    Motheral B; Fairman KA
    Med Care; 2001 Dec; 39(12):1293-304. PubMed ID: 11717571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.
    Fairman KA; Motheral BR; Henderson RR
    Clin Ther; 2003 Dec; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
    Cecil WT; Barnes J; Shea T; Coulter SL
    J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
    Klepser DG; Huether JR; Handke LJ; Williams CE
    J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease.
    Nair KV; Wolfe P; Valuck RJ; McCollum MM; Ganther JM; Lewis SJ
    J Manag Care Pharm; 2003; 9(2):123-33. PubMed ID: 14613341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling the effects of tier-copayment drug benefit designs.
    Curtiss FR
    J Manag Care Pharm; 2003; 9(2):177-8. PubMed ID: 14613348
    [No Abstract]   [Full Text] [Related]  

  • 11. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
    Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
    J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs.
    Nemlekar P; Shepherd M; Lawson K; Rush S
    J Manag Care Pharm; 2013 Oct; 19(8):602-8. PubMed ID: 24074006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
    Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
    Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
    Tseng CW; Brook RH; Keeler E; Mangione CM
    JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation.
    Motheral BR; Henderson R
    Am J Manag Care; 1999 Nov; 5(11):1383-94. PubMed ID: 10662412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not.
    Chang HY; Kan HJ; Shermock KM; Alexander GC; Weiner JP; Kharrazi H
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1282-1290. PubMed ID: 32996394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effect of a consumer-driven health plan on medical care expenditures and utilization.
    Parente ST; Feldman R; Christianson JB
    Health Serv Res; 2004 Aug; 39(4 Pt 2):1189-210. PubMed ID: 15230920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.